6580-95-6Relevant articles and documents
Small molecule that reverses dexamethasone resistance in t-cell acute lymphoblastic leukemia (T-ALL)
Cantley, Alexandra M.,Welsch, Matthew,Ambesi-Impiombato, Alberto,Sanchez-Martin, Marta,Kim, Mi-Yeon,Bauer, Andras,Ferrando, Adolfo,Stockwell, Brent R.
supporting information, p. 754 - 759 (2014/08/05)
Glucocorticoids are one of the most utilized and effective therapies in treating T-cell acute lymphoblastic leukemia. However, patients often develop resistance to glucocorticoids, rendering these therapies ineffective. We screened 9517 compounds, selected for their lead-like properties, chosen from among 3372615 compounds, against a dexamethasone-resistant T-ALL cell line to identify small molecules that reverse glucocorticoid resistance. We synthesized analogues of the most effective compound, termed J9, from the screen in order to define the scaffolds structure-activity relationship. Active compounds restored sensitivity to glucocorticoids through upregulation of the glucocorticoid receptor. This compound and mechanism may provide a strategy for overcoming glucocorticoid resistance in patients with T-ALL.
